Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
Daiichi Sankyo Espha plans to channel profits from existing authorized generics (AGs) into new business areas such as long-listed product (LLP) takeovers, as Japan’s FY2026 drug pricing reform is expected to curb the launch of new AGs. Major pharmacy operator…
To read the full story
Related Article
- Espha Snags Bilanoa AG in Final Pre-Rule Approval Window
February 17, 2026
- Xarelto AG Logs 9.6 Billion Yen on NHI Basis in April-September: Qol
November 10, 2025
BUSINESS
- LinDo Sets Sights on More Pediatric Deals as It Builds Drug-Loss Portfolio
October 6, 2026
- Shionogi to Buy IntraBio for US$2 Billion, Gains Rare Disease Drug
October 6, 2026
- Fujifilm AI Finds Potent New Inhibitors from Known Compound
October 6, 2026
- Boehringer’s Survodutide Makes Mark in Japan PIII Obesity Trial
October 6, 2026
- Kyowa Finds Nitrosamines in 2 Antidepressants; No Recall Planned
October 6, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…